TrialBMC cancer2026

Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.

David Easty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.